Discover personalized clinical trial options designed to support your journey β safely, confidentially, and at no cost.
Takes less than 2 minutes β’ 100% confidential
Breast cancer is the most common cancer in women worldwide, arising from cells in the breast that grβ¦
New breast lump, Size/shape change, Skin dimpling and more.
BRCA1 / BRCA2 gene mutations (hereditary); Dense breast tissue.
Surgery, Radiation Therapy and more.
Overview
Breast cancer is the most common cancer in women worldwide, arising from cells in the breast that grow uncontrollably. It encompasses many subtypes β including hormone receptor-positive, HER2-positive, and triple-negative β each with different behavior and treatment approaches. Survival rates have improved dramatically with early detection and targeted therapies, with 5-year survival exceeding 90% when caught at Stage I or II.
Prevalence
2.3M new cases/year
Worldwide statistics
Symptoms
Common Symptoms
Quality of Life Impact
Treatment affects body image, fertility, fatigue, and emotional wellbeing. With comprehensive survivorship care, most patients return to full activity. Peer support and PAG involvement are key to long-term quality of life.
With the right care and support, most people live full, active lives.
Causes & Risk Factors
Health Insights
Active Global Trials
91+
Across all phases
Symptom Frequency
78%
Patients report primary symptom
Trial Improvement Rate
68%
Report improvement within 3 months
Avg. Trial Duration
14 mo
Median length of participation
Symptom Frequency Among Patients
Treatment
Lumpectomy (breast-conserving) or mastectomy β often combined with sentinel lymph node biopsy.
Typically after lumpectomy to reduce local recurrence risk.
Tamoxifen or aromatase inhibitors for ER+ cancers β taken 5β10 years.
Trastuzumab (Herceptin), pertuzumab, T-DM1 for HER2+ disease.
Neoadjuvant or adjuvant β anthracyclines and taxanes are backbone regimens.
Olaparib / talazoparib for BRCA-mutated early or metastatic breast cancer.
Clinical Trials
Merck Sharp & Dohme
Evaluating whether adding pembrolizumab to chemotherapy improves outcomes in HER2-negative breast cancer.
NCT05723489
Daily Life
You are not alone. Millions of people navigate Breast Cancer every day β and with the right support system and treatments, a meaningful life is absolutely within reach.
Community Support
Connect with thousands of patients and caregivers
Digital Tools
Track symptoms and share insights with your care team
Specialist Network
Access to leading neurologists and researchers
Education Hub
Evidence-based resources tailored to your journey
Check Your Eligibility
Our quick eligibility check matches you with trials that fit your profile β no commitment required.
Age 18+
Open to adult patients across all stages
Breast cancer diagnosis
Any subtype β ER+, HER2+, or triple-negative
Treatment history
Prior chemotherapy, surgery, or newly diagnosed
Takes less than 2 minutes
No cost β’ No obligation β’ No spam
Why Join a Trial
Try innovative therapies before they're widely available β some with breakthrough potential.
Receive close monitoring and support from leading specialists throughout the trial.
Study-related care, tests, and the investigational treatment are provided at no charge.
Research Pipeline
Current pipeline overview for Breast Cancer
Pipeline data is indicative. Source: ClinicalTrials.gov & WHO ICTRP.
Partners
Breast Cancer Foundation
Patient advocacy & education
β PAG EndorsedRARE-UAE
Gulf region patient networks
β PAG EndorsedNews
European Medicines Agency Approves Pembrolizumab in Triple-Negative Breast Cancer
The EMA approved pembrolizumab (Keytruda) in combination with chemotherapy for locally recurrent unresectable or metastatic triple-negative breast cancer.
EMA Β· Feb 28, 2025
FAQ
Resources
NIH MedlinePlus
Authoritative overview of Breast Cancer from the National Institutes of Health.
Visit NIH β
π€Breast Cancer Foundation
Patient advocacy resources, support groups, and disease education.
Visit Foundation β
π¨Emergency Guide
What to do in a Breast Cancer-related emergency β share with family.
Download Guide β
βFAQ β Clinical Trials
Everything you need to know before enrolling in a clinical trial.
Read FAQ β
Your Journey Starts Here
Join thousands of patients who've found the right clinical trial through HEKMA β safely, confidentially, and at no cost.
Check Your EligibilityAstraZeneca
Evaluating olaparib as maintenance therapy for BRCA1/2 mutated HER2-negative metastatic breast cancer.
NCT05312904
